Premium
Virally Inactivated Fresh Frozen Plasma
Author(s) -
Williamson Lorna M.,
Allain J.P.
Publication year - 1995
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1995.tb02590.x
Subject(s) - fresh frozen plasma , virus inactivation , pasteurization , medicine , chemistry , virology , intensive care medicine , virus , food science , immunology , platelet
Abstract Several technologies are now available to treat whole fresh‐frozen plasma (FFP) to inactivate transfusion‐transmitted viruses, including pasteurisation, solvent/detergent and methylene blue/light. The first two involve creating large plasma pools prior to inactivation, while only pasteurisation clearly destroys both enveloped and non‐enveloped viruses. Some of the issues surrounding the use of these products include demonstration of both clinical efficacy and improved viral safety, and the need for product licencing. Potential benefits must be balanced against the risks of plasma pooling, while the increased costs will require comparison with other strategies such as quarantining of plasma. It is also recognised that reducing inappropriate FFP usage will play a role in improved patient safety.